Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 7/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17993275 | 1.00 | SIRT5 (0.44) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL21534468 | 0.96 | SIRT5 (0.48) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL17841852 | 0.94 | SIRT5 (0.49) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL19776854 | 0.94 | SIRT5 (0.49) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL19171358 | 0.90 | SIRT5 (0.40) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL28574926 | 0.90 | GNPAT (0.45) | SIRT5SIRT6SIRT1FURINALB | |
| SCHEMBL18688864 | 0.90 | GNPAT (0.45) | SIRT5SIRT6SIRT1FURINALB | |
| SCHEMBL18122890 | 0.89 | SIRT5 (0.37) | SIRT5SIRT6SIRT1KMT2AFURIN | |
| SCHEMBL16091799 | 0.89 | SIRT5 (0.36) | SIRT5SIRT6SIRT1KMT2AFURIN | |
| SCHEMBL21103418 | 0.89 | SIRT5 (0.36) | SIRT5SIRT6SIRT1KMT2AFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150132-A1 | LIGAND-DRUG CONJUGATES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2024-07-18 | — | — | WO | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | SIRT5 3491/4885SIRT6 2697/4885SIRT1 2691/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | SIRT5 3472/4885SIRT6 2342/4885SIRT1 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.